1-(3,5,6-Trimethylpyridin-2-yl)piperazine → HCID 71252165, 화합물

HRID 2411614노트

반응식

HRID 2411614 반응식
[O:1]=[S:2]1(=[O:18])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:16]=[CH:15][C:10]([C:11]([O:13]C)=O)=[C:9]([CH3:17])[N:8]=1.[CH3:19][C:20]1[C:21]([N:28]2[CH2:33][CH2:32][NH:31][CH2:30][CH2:29]2)=[N:22][C:23]([CH3:27])=[C:24]([CH3:26])[CH:25]=1>>[O:18]=[S:2]1(=[O:1])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[N:8]=[C:9]([CH3:17])[C:10]([C:11]([N:31]2[CH2:32][CH2:33][N:28]([C:21]3[C:20]([CH3:19])=[CH:25][C:24]([CH3:26])=[C:23]([CH3:27])[N:22]=3)[CH2:29][CH2:30]2)=[O:13])=[CH:15][CH:16]=1

참가 물질

3

반응물 2

HCID 584848231-(3,5,6-Trimethylpyridin-2-yl)piperazineHCID 71252256HCID 71252256, 화합물

생성물 1

HCID 71252165HCID 71252165, 화합물수율 62.4%

실험 절차

Using methyl 6-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-2-methylnicotinate (300 mg) described in Preparation Example 37 and 1-(3,5,6-trimethylpyridin-2-yl)piperazine (251 mg) described in Preparation Example 92 and by the reaction and treatment in the same manner as in Example 109, the title compound (307 mg) was obtained.

후처리

  1. customdescribed in Preparation Example 92 and by the reaction and treatment in the same manner as in Example 109

출처 및 근거

ORD 기록
ord-29052010859745d0b4735caf0d28796a
출처 데이터셋
uspto-grants-2014_08
특허 번호
US08816079B2

반응 노트

불러오는 중…